AbbVie And Calibr Announce Expanded Collaboration To Advance Assets In Immunology, Oncology, Neuroscience And Other Areas Of Interest
Portfolio Pulse from Bill Haddad
AbbVie and Calibr have announced an expanded collaboration to advance assets in immunology, oncology, neuroscience, and other areas of interest. The partnership aims to develop and commercialize new therapies in these fields.
July 26, 2023 | 1:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie's expanded collaboration with Calibr could lead to the development and commercialization of new therapies in immunology, oncology, neuroscience, and other areas, potentially boosting its portfolio and revenues.
The expanded collaboration between AbbVie and Calibr could lead to the development of new therapies in various fields. This could potentially increase AbbVie's product portfolio and revenues, positively impacting its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100